Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...

Full description

Bibliographic Details
Main Authors: Antonio Lacquaniti, Patrizio Pasqualetti, Teresa Casuscelli di Tocco, Susanna Campo, Stefania Rovito, Maurizio Bucca, Antonino Ragusa, Paolo Monardo
Format: Article
Language:English
Published: The Korean Society of Nephrology 2020-09-01
Series:Kidney Research and Clinical Practice
Subjects:
anemia
erythropoietin resistance index
ferric carboxymaltose
hemodialysis
Online Access:https://doi.org/10.23876/j.krcp.20.015

Internet

https://doi.org/10.23876/j.krcp.20.015

Similar Items